Menu Search
Equities

Basilea Pharmaceutica AG Allschwil

PK5:STU

Basilea Pharmaceutica AG Allschwil

Actions
  • Price (EUR)32.60
  • Today's Change0.00 / 0.00%
  • Shares traded1.40k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

  • Revenue in CHF (TTM)157.63m
  • Net income in CHF10.45m
  • Incorporated2002
  • Employees147.00
  • Location
    Basilea Pharmaceutica AG AllschwilHegenheimermattweg 167bALLSCHWIL 4123SwitzerlandCHE
  • Phone+41 616061111
  • Fax+41 616061112
  • Websitehttps://www.basilea.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BSLN:SWX since
announced		Transaction
value
Spexis AG-Preclinical Antibiotics ProgramDeal completed15 Jan 202415 Jan 2024Deal completed12.24%2.35m
Data delayed at least 15 minutes, as of May 03 2024 16:30 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.